Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

Objective: Nivolumab improves overall survival (OS) and is associated with fewer adverse events than sorafenib for the treatment of advanced hepatocellular carcinoma (aHCC). However, the cost-effectiveness of nivolumab compared with sorafenib treatment for aHCC remains unclear. This study evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan, Liang, Xueyan, Li, Huijuan, Yang, Tong, Guo, Sitong, Chen, Xiaoyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343987/
https://www.ncbi.nlm.nih.gov/pubmed/35928269
http://dx.doi.org/10.3389/fphar.2022.906956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343987/
https://www.ncbi.nlm.nih.gov/pubmed/35928269
http://dx.doi.org/10.3389/fphar.2022.906956

Ejemplares similares